Phase 1 Clear Cell Renal Cell Carcinoma Clinical Trials
15 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–15 of 15 trials
Recruiting
Phase 1
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Solid TumorsClear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.362 enrolled25 locationsNCT05536141
Recruiting
Phase 1Phase 2
Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Beijing Biotech36 enrolled1 locationNCT07551349
Recruiting
Phase 1Phase 2
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Metastatic Renal Cell CarcinomaCarcinoma, Renal CellAdvanced Renal Cell Carcinoma+8 more
Pfizer224 enrolled49 locationsNCT07227415
Recruiting
Phase 1Phase 2
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
Advanced CancerClear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center100 enrolled1 locationNCT05663710
Recruiting
Phase 1
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Renal Cell CarcinomaClear Cell Renal Cell CarcinomaKidney Cancers+6 more
Neomorph, Inc30 enrolled7 locationsNCT07300241
Recruiting
Phase 1
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Xencor, Inc.307 enrolled23 locationsNCT05433142
Recruiting
Phase 1
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
Stage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Metastatic Clear Cell Renal Cell Carcinoma+3 more
City of Hope Medical Center33 enrolled2 locationsNCT07128680
Recruiting
Phase 1
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
Renal Cell CarcinomaClear Cell Renal Cell Carcinoma
Orhan Kemal Oz35 enrolled1 locationNCT04989959
Recruiting
Phase 1
Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)
Metastatic Clear Cell Renal Cell Carcinoma
NYU Langone Health12 enrolled1 locationNCT07179770
Recruiting
Phase 1Phase 2
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
Stage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Metastatic Clear Cell Renal Cell Carcinoma+3 more
University of Michigan Rogel Cancer Center55 enrolled1 locationNCT06866262
Recruiting
Phase 1Phase 2
Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma
Advanced Clear Cell Renal Cell Carcinoma
Jiangsu Hansoh Pharmaceutical Co., Ltd.104 enrolled1 locationNCT07097935
Recruiting
Phase 1
Imaging of Solid Tumors Using 18F-TRX
Metastatic Malignant Solid NeoplasmStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8+7 more
Rahul Aggarwal56 enrolled1 locationNCT06942104
Recruiting
Phase 1Phase 2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma
Medicenna Therapeutics, Inc.115 enrolled27 locationsNCT05086692
Recruiting
Phase 1
A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors
Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma
Jiangsu Hansoh Pharmaceutical Co., Ltd.60 enrolled1 locationNCT06553339
Recruiting
Phase 1
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
Metastatic Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8+5 more
Osel, Inc.28 enrolled1 locationNCT06399419